These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38367704)

  • 1. Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein.
    Yao Z; Zhang L; Duan Y; Tang X; Lu J
    J Infect; 2024 Mar; 88(3):106121. PubMed ID: 38367704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens.
    Duan L; Zheng Q; Zhang H; Niu Y; Lou Y; Wang H
    Front Immunol; 2020; 11():576622. PubMed ID: 33117378
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural Plasticity and Immune Evasion of SARS-CoV-2 Spike Variants.
    Ghimire D; Han Y; Lu M
    Viruses; 2022 Jun; 14(6):. PubMed ID: 35746726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic Evolution of SARS-CoV-2 in West Sumatra: Analyzing S Gene Mutations Across Variants and Their Impact on Public Health and Vaccine Strategies.
    Linosefa L; Hasmiwati H; Jamsari J; Putra AE
    Pak J Biol Sci; 2024 Mar; 27(4):182-189. PubMed ID: 38812109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unraveling the Dynamics of Omicron (BA.1, BA.2, and BA.5) Waves and Emergence of the Deltacton Variant: Genomic Epidemiology of the SARS-CoV-2 Epidemic in Cyprus (Oct 2021-Oct 2022).
    Chrysostomou AC; Vrancken B; Haralambous C; Alexandrou M; Gregoriou I; Ioannides M; Ioannou C; Kalakouta O; Karagiannis C; Marcou M; Masia C; Mendris M; Papastergiou P; Patsalis PC; Pieridou D; Shammas C; Stylianou DC; Zinieri B; Lemey P; The Comessar Network ; Kostrikis LG
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling coronavirus spike protein dynamics: implications for immunogenicity and immune escape.
    Kunkel G; Madani M; White SJ; Verardi PH; Tarakanova A
    Biophys J; 2021 Dec; 120(24):5592-5618. PubMed ID: 34767789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The human microbiota is a beneficial reservoir for SARS-CoV-2 mutations.
    Cao B; Wang X; Yin W; Gao Z; Xia B
    mBio; 2024 May; 15(5):e0318723. PubMed ID: 38530031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The SARS-CoV-2 Spike Glycoprotein as a Drug and Vaccine Target: Structural Insights into Its Complexes with ACE2 and Antibodies.
    Papageorgiou AC; Mohsin I
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105869
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emergence and Re-emergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target.
    Ahmad F; Kamal MA; Tekwani BL
    Curr Pharm Des; 2021; 27(33):3566-3576. PubMed ID: 33327904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies.
    Almehdi AM; Khoder G; Alchakee AS; Alsayyid AT; Sarg NH; Soliman SSM
    Infection; 2021 Oct; 49(5):855-876. PubMed ID: 34339040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
    Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
    Elife; 2022 Jan; 11():. PubMed ID: 35072628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.
    Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S
    Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting intra-viral conserved nucleocapsid (N) proteins as novel vaccines against SARS-CoVs.
    Thura M; Sng JXE; Ang KH; Li J; Gupta A; Hong JM; Hong CW; Zeng Q
    Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34519332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains.
    Qing E; Kicmal T; Kumar B; Hawkins GM; Timm E; Perlman S; Gallagher T
    mBio; 2021 Aug; 12(4):e0159021. PubMed ID: 34340537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Uncovering the impact of SARS-CoV2 spike protein variants on human receptors: A molecular dynamics docking and simulation approach.
    Zaheer M; Ali N; Javed H; Munir R; Jamil N
    J Infect Public Health; 2023 Oct; 16(10):1544-1555. PubMed ID: 37566991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
    Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
    mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
    Arevalo-Romero JA; Chingaté-López SM; Camacho BA; Alméciga-Díaz CJ; Ramirez-Segura CA
    Heliyon; 2024 Mar; 10(5):e26423. PubMed ID: 38434363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.